Florida State University researchers are giving oncologists another tool in their fight against pediatric brain cancer.
In work published in Bioactive Materials, a research team led by Department of Chemistry and Biochemistry Professor Qing-Xiang “Amy” Sang showed the possibility of enhancing natural killer immune cells to improve their ability to attack a rare pediatric brain cancer.
Natural killer cells can target all types of cancer, and previous research has examined their effectiveness as a therapy. But this is one of the first studies to test the ability of natural killer cells to destroy a specific variety of cancer known as a malignant rhabdoid tumor. When this tumor appears in the central nervous system, it is called an atypical teratoid rhabdoid tumor (ATRT). Although it is a rare disease, it accounts for 20% of all central nervous system tumors in children younger than 3.
Natural killer cells are a critical part of the human immune system, but they can be overwhelmed by cancer cells. Sang’s research team wanted to see if they could help the fight against this disease and develop a treatment with fewer side effects than traditional approaches such as chemotherapy or radiation therapy.
The researchers derived natural killer cells from human-induced pluripotent stem cells — cells from skin or blood that have been reprogrammed back into an embryonic-like state, allowing them to develop into any type of human cell. Unlike feeder cells from mice, which are typically used in similar studies, human-induced pluripotent stem cell-derived natural killer cells don’t pose a risk of rejection by a patient’s immune system.
They also enhanced the immune quality of those cells by using different proteins to stimulate them to have a stronger killing power.
Although more work is needed to develop a ready-to-use therapy for cancer patients, the research shows that natural killer cells derived from human-induced pluripotent stem cells could be the basis for future medicines to treat pediatric brain tumors.
